<DOC>
	<DOCNO>NCT02378649</DOCNO>
	<brief_summary>A randomize , placebo control , single center clinical trial evaluation efficacy safety Sildenafil administration cardiac ICU follow Mitral Valve ( MV ) Surgery patient pre-operative Significant Pulmonary Hypertension .</brief_summary>
	<brief_title>PDEI Following Mitral Valve Surgery Patients With Pulmonary Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>1 . Age â‰¥ 22 2 . Undergoing mitral valve surgery ( either repair replacement ) without coronary revascularization , aortic valve replacement ( AVR ) repair ; tricuspid valve surgery . 3 . Preoperative pulmonary arterial systolic pressure &gt; 50 mm Hg determine rest echocardiography postoperative sPAP &gt; 45 mmHg obtain invasive hemodynamics measurement . 4 . Willing able give write informed consent prior procedure 1 . Hypersensitivity study drug 2 . Women childbearing potential 3 . Expected need administer nitrate clinically indicate perioperatively 4 . Postoperative hypotension ( systolic blood pressure ( BP ) &lt; 80 ) evidence shock ( postoperative evidence kind shock ) 5 . Cardiac systemic amyloidosis 6 . Active malignancy BCC ( basal cell carcinoma ) 7 . Stable kidney dysfunction Creatine clearence ( CrCl ) &lt; 30 mL/min screen period hepatic failure mild 8 . Significant anemia ( hemoglobin &lt; 8 mg/dl ) preoperative . 9 . Known drug alcohol dependence factor interfere study conduct interpretation result opinion investigator suitable participate ; 10 . Any illness cardiac might reduce life expectancy le 1 year screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Pulmonary Hypertension</keyword>
</DOC>